Fujii N, Katsuyama T, Kobayashi E, Hara M, Nakano H
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
J Antibiot (Tokyo). 1995 Aug;48(8):768-72. doi: 10.7164/antibiotics.48.768.
In the course of screening for microbial products with antitumor activity, new antitumor agents, clecarmycins, were isolated from culture broth of Streptomyces sp. DO-114. The antibiotics were produced in a fermentation medium supplemented with a highly porous polymer resin which adsorbs antibiotics and results in a increase of titer. Active materials were separated from the polymer resin by solvent extraction procedure and two components named clecarmycin A1 and C were isolated by silica gel column chromatography. These were active against bacteria, and showed antiproliferative activities against human HeLa S3 cells. Clecarmycins exhibited antitumor activity against leukemia P388 and sarcoma 180 in mice.
在筛选具有抗肿瘤活性的微生物产物过程中,从链霉菌属DO-114的培养液中分离出了新型抗肿瘤药物——克利卡霉素。这些抗生素是在添加了一种能吸附抗生素并提高效价的高孔隙率聚合物树脂的发酵培养基中产生的。通过溶剂萃取法从聚合物树脂中分离出活性物质,并通过硅胶柱色谱法分离出两种成分,分别命名为克利卡霉素A1和C。它们对细菌有活性,对人HeLa S3细胞显示出抗增殖活性。克利卡霉素对小鼠白血病P388和肉瘤180具有抗肿瘤活性。